MAPT and Alzheimer disease: Disruption of TFEB-mediated signaling has been reported to exacerbate tau pathology [4, 5], while TFEB overexpression in neurons and astrocytes may enhance the clearance of Aβ and tau in mouse models of AD [6–8], highlighting a strong link between lysosomal dysfunction and AD pathology.